Search clinical trials for: CRA-24781

Total 5399 results

Fred Hutchinson Cancer Center

Terminated

Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Recurrent Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Burkitt Lymphoma | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Acute Leukemia in Remission | Acute Undifferentiated Leukemia | Acute Biphenotypic Leukemia and other conditions

United States
Mehrdad Abedi, MD
Amgen

Completed

Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma

Stage IV Adult Lymphoblastic Lymphoma | Contiguous Stage II Adult Lymphoblastic Lymphoma | Noncontiguous Stage II Adult Lymphoblastic Lymphoma | Stage I Adult Lymphoblastic Lymphoma | Stage III Adult Lymphoblastic Lymphoma | Untreated Adult Acute Lymphoblastic Leukemia

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia

Leukemia

United States, Canada, Netherlands, Puerto Rico, Switzerland
M.D. Anderson Cancer Center

Active, not recruiting

Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Acute Myeloid Leukemia With BCR-ABL1

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Burkitt Lymphoma | Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | CD20 Positive | Adult Acute Lymphoblastic Leukemia in Complete Remission | Childhood Acute Lymphoblastic Leukemia in Complete Remission | Burkitt Leukemia

United States
St. Jude Children's Research Hospital
Baylor College of Medicine; Gateway for Cancer Research

Active, not recruiting

Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I

Acute Lymphoblastic Leukemia

United States, Canada
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Adult Acute Myeloid Leukemia in Remission | Adult Acute Lymphoblastic Leukemia in Remission | Refractory Anemia With Excess Blasts | Refractory... and other conditions

United States
St. Jude Children's Research Hospital
National Cancer Institute (NCI); National Institute of General Medical Sciences... and other collaborators

Completed

Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes) for the Treatment of Primary Central Nervous System Lymphoma

Central Nervous System Lymphoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

B-cell Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia

United States, Canada, Australia, Switzerland
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia in Remission | Childhood Acute Myeloid Leukemia in Remission | Adult Acute Lymphoblastic Leukemia in Remission | Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent... and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia

Leukemia

United States, Canada, Australia, Switzerland, Puerto Rico, Netherlands
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia

Leukemia

United States, Australia, Canada
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

Lymphoma | Leukemia

United States, Switzerland, Canada, Netherlands, Puerto Rico, Australia
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia

Myeloid Neoplasm | Childhood Acute Promyelocytic Leukemia With PML-RARA

United States, Canada, Puerto Rico
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Lymphoma | CD20 Positive | Lymphocytic Neoplasm

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET

Medulloblastoma | Anaplastic Medulloblastoma

United States, Canada, Puerto Rico, Australia, Netherlands
Jonsson Comprehensive Cancer Center
Bristol-Myers Squibb; National Cancer Institute (NCI); Eunice Kennedy Shriver... and other collaborators

Completed

Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1 (NYM)

Childhood Solid Neoplasm | Metastatic Neoplasm | Adult Solid Neoplasm

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma

Lymphoma

United States, Canada, Australia, Switzerland, Puerto Rico
GlaxoSmithKline

Completed

Validation Study of Multiple Probe Compounds for Drug Interaction Evaluation

Drug Interactions

Korea, Republic of
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes

Leukemia

United States, Canada, Australia, Switzerland, New Zealand
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia | Ph-Like Acute Lymphoblastic Leukemia

United States
National Cancer Institute (NCI)

Completed

Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Myelodysplastic Syndrome With Excess Blasts | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome | Adult Acute Monoblastic Leukemia | Adult Acute Monocytic Leukemia | Adult Acute Myeloid Leukemia... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

Primary Myelofibrosis | Secondary Myelofibrosis

United States
National Cancer Institute (NCI)

Completed

Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Recurrent Adult Lymphoblastic Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | B-cell Adult Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood... and other conditions

United States, Canada, Australia, Puerto Rico
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib

Diffuse Large B-Cell Lymphoma Unclassifiable

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Hodgkin Lymphoma | Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Acute Leukemia | Myelodysplastic Syndrome | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Myeloproliferative... and other conditions

United States
Second Affiliated Hospital, School of Medicine,...
Fudan University; Peking Union Medical College Hospital; West China Hospital; The... and other collaborators

Recruiting

Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome (PETARDS)

Acute Respiratory Distress Syndrome

China
Emory University
National Cancer Institute (NCI); Janssen Scientific Affairs, LLC

Recruiting

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

Renal Failure | Plasma Cell Myeloma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Recurrent Hodgkin Lymphoma | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Recurrent Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic... and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia

Juvenile Myelomonocytic Leukemia

United States, Canada, Australia, New Zealand
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)

Recurrent Childhood Acute Lymphoblastic Leukemia

United States, Australia, Canada, Puerto Rico
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Recurrent B Lymphoblastic Lymphoma | Refractory B Lymphoblastic Lymphoma

United States, Puerto Rico
Northwestern University
National Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.

Active, not recruiting

Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma

Diffuse Large B-Cell Lymphoma | Plasmablastic Lymphoma | B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma | Adult Burkitt Lymphoma | MYC Gene Mutation

United States
St. Jude Children's Research Hospital
Assisi Foundation; Cookies for Kids' Cancer

Completed

Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood B-Lymphoblastic Lymphoma

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

T-cell Childhood Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic Leukemia

United States
National Cancer Institute (NCI)

Completed

Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma

Childhood Diffuse Large Cell Lymphoma | Childhood Immunoblastic Large Cell Lymphoma | Childhood Burkitt Lymphoma | Untreated Childhood Acute Lymphoblastic Leukemia | Stage I Childhood Large Cell Lymphoma | Stage I Childhood Small Noncleaved Cell Lymphoma | Stage II Childhood Large Cell Lymphoma | Stage II Childhood Small Noncleaved Cell Lymphoma and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma

Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory T Acute Lymphoblastic Leukemia | Recurrent T Acute Lymphoblastic Leukemia

United States
M.D. Anderson Cancer Center

Active, not recruiting

Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Untreated Adult Acute Lymphoblastic Leukemia | Accelerated Phase Chronic Myelogenous Leukemia,... and other conditions

United States
National Cancer Institute (NCI)

Completed

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

Anaplastic Large Cell Lymphoma, ALK-Positive | Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma | Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma | Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System

Childhood Atypical Teratoid/Rhabdoid Tumor

United States, Canada, Australia
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease

Stage III Childhood Hodgkin Lymphoma | Stage IV Childhood Hodgkin Lymphoma | Stage I Childhood Hodgkin Lymphoma | Stage II Childhood Hodgkin Lymphoma | Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma | Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma | Childhood Mixed Cellularity... and other conditions

United States, Canada, Australia, New Zealand, Puerto Rico, Switzerland, Israel
M.D. Anderson Cancer Center

Withdrawn

Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer

Malignant Glioma | Medulloblastoma | Anaplastic Ependymoma | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Atypical Teratoid/Rhabdoid Tumor | Primitive Neuroectodermal Tumor | Choroid Plexus Carcinoma | Recurrent Atypical Teratoid/Rhabdoid Tumor | Malignant Brain Neoplasm | Central Nervous System... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Recruiting

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Acute Leukemia | Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

Hematopoietic and Lymphoid Cell Neoplasm

United States
St. Jude Children's Research Hospital
Incyte Corporation; Amgen; Servier

Active, not recruiting

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Acute Lymphoblastic Leukemia | Acute Lymphoblastic Lymphoma

United States, Australia

Search clinical trials for: CRA-24781

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations